Picture of ACADIA Pharmaceuticals logo

ACAD — ACADIA Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Momentum

Relative Strength (%)
1m-20.36%
3m+13.64%
6m-10.87%
1yr-68.21%
Volume Change (%)
10d/3m-12.4%
Price vs... (%)
52w High-61.63%
50d MA-3.88%
200d MA+0.99%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-30.65%
Return on Equity-31.35%
Operating Margin-40.67%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of ACADIA Pharmaceuticals EPS forecast chart

Profile Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
January 16th, 1997
Public Since
May 27th, 2004
No. of Shareholders
68,000
No. of Employees
570
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
160,755,971

ACAD Share Price Performance

Latest News for ACAD

Upcoming Events for ACAD

Q4 2021 ACADIA Pharmaceuticals Inc Earnings Release

Q1 2022 ACADIA Pharmaceuticals Inc Earnings Release

ACADIA Pharmaceuticals Inc Annual Shareholders Meeting

Similar to ACAD

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Achilles Therapeutics

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email